VivaZome Therapeutics and Cytiva, formerly part of GE Healthcare Life Sciences, have entered into an agreement where Cytiva’s range of purification...
Read More »VivaZome licenses University of Adelaide stem cell technology to support development and commercialization of exosome-based therapeutics
VivaZome Therapeutics Pty Ltd and the University of Adelaide today announced that they have entered into a series of agreements encompassing licensing of...
Read More »Sienna and VivaZome to Evaluate EXO-NETs for VivaZome’s Exosome-based Therapeutics
Sienna Cancer Diagnostics Ltd (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative In-Vitro Diagnostic (IVD) tests, has entered into an agreement with Melbourne-based VivaZome Therapeutics Pty...
Read More »Korean and Australian biotech firms collaborate to develop exosome-based therapies
VivaZome Therapeutics Pty Ltd (“VivaZome”) and ToolGen, Inc (“ToolGen”) have announced the execution of a collaborative research and option agreement to explore gene-editing of cells for enhanced exosome production. Under the agreement...
Read More »